Background-Few
C ardiovascular disease remains the leading cause of death among kidney transplantation patients. 1,2 Cardiac disease accounts for 43% of all-cause mortality among dialysis patients and for Ϸ38% of all-cause mortality after transplantation. 1, 3 The number of kidney transplantations (including combined kidney/pancreas) performed annually increased gradually from 3784 in 1980 2 to a peak of 18 018 in 2006, with a small decline to 17 356 in 2008. 4 Five-year survival for kidney transplantation patients is 80.3% for deceased-donor recipients and 89.5% for living-donor recipients; survival has gradually improved over the past 3 decades. 1, 2 In 2008, 15% of kidney transplantations were performed in patients Ն65 years of age compared with 9% in 2000. 1, 2, 4 With improved survival and with increased numbers of older patients receiving transplants, the number of kidney transplantation patients at risk for developing cardiac disease is likely to increase over time.
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Valvular heart disease is common in patients undergoing renal replacement therapy. 5, 6 Incidence in dialysis patients from 1992 to 1997 was 3.37 per 1000 person-years, 5 times the incidence in the general population. 6 Mortality among dialysis patients hospitalized for valvular heart disease is high compared with all other dialysis patients (adjusted hazard ratio [HR] by Cox regression, 1.35; 95% confidence interval [CI], 1.25 to 1.46). 5, 6 Increased calcification rate is an important aspect of left-sided valvular disease in end-stage renal disease (ESRD) patients 7 ; the rate of aortic stenosis progression is Ϸ3 times faster in dialysis patients than in the general population (0.23 versus 0.05 to 0.1 cm 2 /y). 8 Use of bioprosthetic heart valves in hemodialysis patients was proscribed in past American College of Cardiology/ American Heart Association guidelines, reflecting a widely held (but poorly supported) perception of a high incidence of bioprosthetic valve failure mandating implantation of mechanical prosthetic valves in these patients. 9 In our 2002 article on outcomes of dialysis patients after heart valve replacement surgery, 10 we reported an estimated 2-year mortality of 60%, with no difference in survival for tissue versus nontissue valves. Reflecting these new data, revised 2006 practice guidelines rescinded the proscription of bioprosthetic valves in dialysis patients. 9, 11 No specific practice guidelines have been directed toward valve selection for ESRD patients who undergo kidney transplantations. Because of our previous work with dialysis patients, we wondered about transplantation patient survival after cardiac valvular surgery and about the potential contribution of prosthesis type to outcome. Because transplantation patients receive ongoing immunosuppression, often including steroid therapy, their outcomes might be different with respect to prosthetic valve type.
Data on survival of kidney transplantation patients after cardiac valve replacement are few, and no data have been published on the association of tissue-versus nontissue-valve selection and outcome. The purpose of the present study was to assess the survival of kidney transplantation patients in the United States after cardiac valve replacement and to compare valve selection and associated patient survival.
Methods
All data were derived from the US Renal Data System (USRDS). The accuracy of these data has been validated previously. 12 This was a retrospective cohort study of kidney transplantation patients hospitalized for first heart valve replacement surgery after initiation of renal replacement therapy from January Associations of comorbid conditions were examined because patient survival is significantly affected by comorbidity. 13, 14 We used a previously developed comorbidity profiling methodology based on ICD-9-CM diagnosis and procedure codes in the Medicare Part A institutional inpatient claims. 15 Comorbid conditions, identified by ICD-9-CM codes from hospitalizations that occurred before the valve surgery, include prior acute myocardial infarction, other atherosclerotic heart disease, congestive heart failure, other cardiac conditions (including valvular heart disease, arrhythmia, and arrhythmia requiring pacemaker), nonskin malignancies, peripheral vascular disease, cerebrovascular ischemia (cerebrovascular accident and transient ischemic attack), chronic obstructive pulmonary disease, gastrointestinal disease, gallbladder disease, and liver disease. We also calculated a version of the Charlson score adapted for use with administrative databases, 16, 17 which provides a means of assessing comorbidity and overall mortality by accounting for the presence or absence of 19 different conditions that are scored and summed. Each condition is weighted according to its potential to influence mortality. 16 We grouped patients according to Charlson scores of 0, 1, 2, or Ն3. 16 Because a preliminary analysis found no difference in outcomes using individual comorbid conditions compared with the Charlson score in the Cox model, we retained the Charlson score in the Cox model.
In-hospital mortality was determined, and survival time was calculated from time of valve surgery to censoring or study end point (all-cause death). Follow-up began at the time of surgery and ended at death or December 31, 2004, whichever occurred first. Patients were censored only if lost to follow-up. Cause of death was ascertained from the Centers for Medicare and Medicaid ESRD Death Notification (form CMS-2746). Hospitalization rates for gastrointestinal hemorrhage and bacterial endocarditis were also calculated.
Patient characteristics were compared by use of the 2 test. Survival was estimated by the life-table method. 18 The log-rank test was used to compare the difference in cumulative survival in different groups. Patients who received both tissue and nontissue valves (nϭ6) were excluded from the survival comparison of tissue versus nontissue valves. Only patients who received aortic or mitral valve replacements were included in the survival analysis. A Cox proportional-hazards model was used to evaluate the associations of independent predictors (demographics, comorbidity, duration of ESRD before valve surgery, concomitant CAB, and type of valve surgery by valve site and prosthesis) on patient survival. 19 The reported P values in the Cox model are based on the Wald test statistic. A propensity score approach was also investigated through the use of a logistic regression model to compute the probability of receiving a tissue valve based on all patient characteristics and comorbid conditions. Two approaches were then used: entering the propensity scores into the final proportional-hazards model and running 4 separate models within quartiles of propensity score. All reported P values are 2 sided. All statistical analyses were performed with the SAS system for Windows, version 9.1 (SAS Institute, Inc, Cary, NC).
Results
Our final cohort included 1335 kidney transplantation patients hospitalized for aortic or mitral valve replacement or both. Mean follow-up time was 34.4Ϯ34.5 months (25th to 75th percentile range, 6.35 to 51.17 months); median follow-up time was 23.97 months. The cohort was 62.6% men and 37.4% women; 78% were white, 18% were black, and 4% were other races ( Aortic valve replacement was performed in 66% of patients, mitral valve replacement in 25%, and combined aortic and mitral valve replacement in 9%. Tissue valves were used in 31% of aortic, 22% of mitral, and 17% of combined aortic and mitral valve replacement surgeries. Concomitant CAB was performed in 38% of patients. Tissue valves were used in 369 patients (28%); nontissue valves were used in 966 (72%). Median ESRD duration was 8.0 years for the overall cohort (25th percentile, 4.9 years; 75th percentile, 12.3 years), 8.4 years for patients receiving tissue valves (25th percentile, 5.2 years; 75th percentile, 12.7 years), and 7.8 years for patients receiving nontissue valves (25th percentile, 4.8 years; 75th percentile, 12.1 years). Charlson scores were 0 and 1 for most patients.
The association of independent predictors of all-cause mortality was examined in the Cox proportional-hazards model (reported HRs are adjusted for other factors in the model). The most powerful predictors of death were age Ͼ75 Figure) .
Inclusion of propensity scores in the Cox model did not appreciably change the HRs of interest (HR for tissue versus nontissue valves, 0.81; 95% CI, 0.67 to 0.99 after inclusion of propensity scores). HRs from separate Cox models within Cause-specific mortality was categorized as cardiovascular, infection, or other/unknown cause. For patients undergoing valve surgery before 2000 who subsequently died (nϭ514), cause of death was cardiovascular in 26.6%, infection in 13.9%, and other/unknown in 59.5% for those with tissue valves and cardiovascular in 29.4%, infection in 14.3%, and other/unknown in 56.3% for those with nontissue valves (Pϭ0.86 for tissue versus nontissue). Of patients undergoing valve surgery in 2000 to 2004, 315 died. Cause of death was cardiovascular in 32.1%, infection in 11.6%, and other/unknown in 56.3% for those with tissue valves and cardiovascular in 28.1%, infection in 14.8%, and other/ unknown in 57.1% for those with nontissue valves (Pϭ0.62 for tissue versus nontissue).
The estimated hospitalization rate for endocarditis was 5.0 per 100 patient-years for patients with tissue valves and 5.2 per 100 patient-years for patients with nontissue valves (Pϭ0.79). The rate for gastrointestinal hemorrhage was 4.4 per 100 patientyears for patients with tissue valves and 5.2 per 100 patient-years for patients with nontissue valves (Pϭ0.42).
Discussion
We previously reported that estimated 2-year mortality after cardiac valvular replacement surgery is Ϸ60% among ESRD patients requiring dialysis. 10 In the present study of another group of ESRD patients, those who undergo kidney transplantation, 2-year mortality after cardiac valvular surgery was Ϸ40% and in-hospital death was Ϸ14% compared with our previously reported 19% among dialysis patients. 10 Few prior studies provide meaningful data on valvular surgery in kidney transplantation patients. Dresler et al 20 reported on 45 kidney transplantation patients, of whom 13 underwent isolated cardiac valve replacement and 1 underwent CAB and valve replacement. Valve replacements included 4 aortic, 3 mitral, 2 aortic and mitral, 2 aortic with replacement of ascending aorta, 1 aortic and mitral with ventricular myotomy, and 1 aortic and mitral with tricuspid reconstruction. In-hospital mortality was 28.6%, and 8 of 13 patients were alive at the end of 5 years. Bioprosthetic valves were used in 2 patients in the aortic position and in 1 patient in the mitral position. Our in-hospital mortality of 15.1% for patients who received nontissue valves is comparable to results shown by Musci et al, 21 who retrospectively analyzed outcomes of heart valve operations done in solid-organ transplantation patients over an 18-year period. The study, done at a single hospital center in Germany, included cardiac valve operations in 16 kidney transplantation patients (9 aortic, 3 mitral, 2 aortic and mitral, 1 mitral valve reconstruction, and 1 tricuspid valve reconstruction). Three patients died in hospital for an in-hospital mortality rate of 18.7%. Long-term survival was 81% at a mean follow-up time of 41.2 months. Mechanical valves were used in all the surgeries.
Our observed survival is poorer than reported in other studies, [22] [23] [24] [25] [26] [27] [28] but the small sample size in these earlier studies and the inclusion of nonvalvular surgery preclude any meaningful comparison. None of these studies compared the outcome of tissue versus nontissue valves. The major significance of the present study of 1335 patients is that it provides a point of national reference for survival outcome of kidney transplantation patients after cardiac valve replacement.
In our study, in-hospital death was 11.4% for patients who received tissue valves and 15.0% for patients who received nontissue valves. The overall risk of mortality was reduced by 19% for patients who received tissue valves compared with those who received nontissue valves (HR, 0.81; 95% CI, 0.67 to 0.99) in a propensity-adjusted Cox model, but there was no significant difference in unadjusted survival.
Several potential explanations could account for the more favorable outcome for patients who receive tissue valves. Implantation of nontissue (mechanical) valves requires lifelong therapy with oral anticoagulation. Thrombotic complications would be expected to occur more frequently with nontissue valves, and long-term oral anticoagulation is accompanied by increased risk of hemorrhage. Kidney transplantation patients, who often receive immunosuppression with steroids, might be expected to be more susceptible to the additional (gastrointestinal) hemorrhagic risk posed by longterm anticoagulation. We found that the rate of hospitalizations resulting from gastrointestinal hemorrhage was Ϸ20% higher among patients with nontissue versus tissue valves, but the difference was not statistically significant. We found a nonsignificant 16% reduction in mortality (HR, 0.84; 95% CI, 0.69 to 
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1991 to 1995, possibly reflecting improvements in care, including less intense maintenance immunosuppression. Our data indicate that kidney transplantation patients with prosthetic heart valves are at increased risk for bacterial endocarditis. In a prior study of 47 899 kidney transplantation patients, we found an incident rate of endocarditis of 2.72 per 1000 patient-years. 29 In the present study of kidney transplantation patients with prosthetic valves, endocarditis incidence was nearly 20-fold higher than in our prior study, but there was no evidence for a difference in endocarditis risk related to valve selection.
Our study has several limitations. The USRDS database provides few clinical data. Important prognostic factors such as left ventricular function and functional class are not identified in the database. Ascertainment of valve replacement type is based on claims data. Although published data exist on the accuracy of claims information compared with clinical data in patients with ischemic heart disease, 30 we are unaware of any specific studies about validation of claims data accuracy for patients undergoing cardiac valve replacement. Our survival analysis is based on a retrospective study design; selection bias for a particular choice of valve could possibly have occurred, and our propensity model may not account for the contribution of all significant unknown confounders.
Our data suggest a minimal reduction in mortality risk associated with the use of tissue valves in renal transplantation patients requiring valve surgery. Although the proportion of tissue valves has increased over time, even in 2000 to 2004, they accounted for only 38% of valve implants. From the perspective of clinical management, even if survival outcomes were similar for tissue and nontissue valves (ie, no difference in unadjusted survival or adjusted mortality risk), some clinicians and patients might favor tissue valves because tissue valve implantation is not associated with the additional potential hazard of long-term anticoagulation (and the definite inconvenience of attendant monitoring of therapy).
Conclusions
The overall 2-year mortality of renal transplantation patients after left-sided cardiac valvular replacement is Ϸ40% (regardless of prosthetic valve type). The additional requirement for long-term anticoagulation with nontissue valves might support the preferential use of tissue valves by clinicians and their patients who wish to avoid warfarin therapy.
